The efficacy of oral doxycycline with Bevacizumab in diabetes

Phase 3

• Conditions: Type 1 diabetes mellitus with ophthalmic complications; E11.3; Condition 1: Diabetes, Clinically significant macular edema. Condition 2: Diabetes, Clinically significant macular edema.; Type 2 diabetes mellitus with ophthalmic complications; E10.3

• Registration Number: IRCT20200720048150N1
• Lead Sponsor: Ahvaz University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 30 November 2020

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Diabetic patients with confirmed Clinically Significant Macular Edema

Exclusion Criteria

Patients with previous history of surgery for retinal detachment
Patients with glaucoma
Patients with uveitis
Patients with macular geographic atrophy
Patients with macular scar
Patients with gastrointestinal distress

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Central macular thickness. Timepoint: Before intervention and 2, 4, 6 and 9 months after intervention. Method of measurement: Optical Coherence Tomography images were generated using the Fast Macular Thickness Scan consisting of six radial scans oriented 30 degrees from one another, each having a 2?mm axial depth and 6?mm transverse length. Each image had 10?µm axial and 20?µm transverse resolutions in tissue and consisted of 1024 axial pixels by 512 transverse pixels with a maximum scan velocity of 400 axial per second.